The primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) has a poor prognosis. R-CHOP with or without radiotherapy is the available recommendations for first-line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second-line treatment of relapsed PCDLBCL-LT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509882PMC
http://dx.doi.org/10.1002/ccr3.2137DOI Listing

Publication Analysis

Top Keywords

primary cutaneous
8
cutaneous diffuse
8
diffuse large
8
large b-cell
8
b-cell lymphoma
8
lymphoma leg
8
leg type
8
effectiveness lenalidomide
4
lenalidomide relapsed
4
relapsed primary
4

Similar Publications

Exploring the Research Focus of RNA-Binding Proteins in Trauma and Burns.

Anal Cell Pathol (Amst)

December 2024

Department of Burn Surgery, The First Affiliated Hospital of Naval Medical University, People's Republic of China, Research Unit of Key Techniques for Treatment of Burns and Combined Burns and Trauma Injury, Chinese Academy of Medical Sciences, No. 168 Changhai Road, Shanghai 200433, China.

Trauma and burns are leading causes of death and significant global health concerns. RNA-binding proteins (RBPs) play a crucial role in post-transcriptional gene regulation, influencing various biological processes of cellular RNAs. This study aims to review the emerging trends and key areas of research on RBPs in the context of trauma and burns.

View Article and Find Full Text PDF

Cutaneous melanoma is the deadliest form of skin cancer. Despite advancements in treatment, many patients still face poor outcomes. A deeper understanding of the mechanisms involved in melanoma pathogenesis is crucial for improving diagnosis and therapy.

View Article and Find Full Text PDF

Background: Online digital materials are integral to patient education and health care outcomes in dermatology. Acanthosis nigricans (AN) is a common condition, often associated with underlying diseases such as insulin resistance. Patients frequently search the internet for information related to this cutaneous finding.

View Article and Find Full Text PDF

Sebaceous carcinoma in immunosuppressed patients: a narrative review.

Arch Dermatol Res

January 2025

Department of Dermatology, Columbia University Irving Medical Center, 161 Ft Washington Ave, 12th Floor, New York, NY, 10032, USA.

Sebaceous carcinoma is a rare cutaneous malignancy of sebaceous glands, but it is up to 25-fold more common in immunosuppressed individuals. In this narrative review, we examine the current literature on the pathogenesis, incidence, risk factors, prognosis, treatment, and surveillance of sebaceous carcinoma in immunosuppression and highlight practical considerations for providers who care for these patients. Increased incidence may be related to decreased immune surveillance, susceptibility to an unknown viral trigger, microsatellite instability, immunosuppressive medications, and unmasking of occult Muir-Torre Syndrome.

View Article and Find Full Text PDF

Background: Topical retinoids, while renowned for their efficacy in treating acne vulgaris, are often hampered by inter-individual variability in tolerability. This challenge, primarily driven by side effects like erythema, scaling, and dryness, significantly impacts patient adherence and, ultimately, treatment outcomes.

Aims: This prospective, multi-center, observational study investigated the novel role of a specific dermocosmetic regimen as adjunctive therapy, focusing on its ability to mitigate retinoid-induced side effects and enhance the overall tolerability of acne treatment regimens in a Korean population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!